Influence of calcium channel antagonist on the pharmacodynamics of a second-generation sulfonylurea in rats and rabbits

T E Gopala Krishna Murthy, C Mayuren


Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose concentration known as hyperglycemia. Diabetes mellitus covers a wide range of heterogeneous diseases and involves management of its
associated acute and chronic complications; thus, there is every possibility of administering other drugs along with the primary anti-diabetic agent, which may be the cause for a drug-drug interaction to occur. In the present study, the possible pharmacodynamic interaction was studied with amlodipine besylate and gliclazide in diabetic rats and healthy rabbits. The animals were divided into three groups. Gliclazide was studied at a dose of 1.44 mg/200 g and 5.6 mg/1.5 kg body weight in rats and rabbits respectively. Amlodipine besylate at a dose of 0.090 mg/200 g and 0.350 mg/1.5 kg body weight was used for the interaction study in rats and rabbits respectively. The drugs were administered orally and the blood samples were collected before and after administration of drug for a period of 16 h in rats and 24 h in rabbits. The serum samples were then subjected to glucose estimation by glucose peroxides method. The percentage reduction in blood glucose levels were calculated with respect to initial levels. Gliclazide showed a significant reduction of elevated and normal blood glucose
levels. The extent of blood glucose reduction was comparatively reduced in the case of combination therapy of amlodipine besylate and gliclazide. The study also suggests the necessity to readjust the dose of gliclazide when co-administered with amlodipine besylate.

Full Text:



Bastaki S. Diabetes mellitus and its treatment. Int J Diabetes Metab


Hardman JG, Limbird LE. Goodman and Gilman’s The pharmacological

basics of therapeutics. 9th ed. New York: McGraw Hill; 1996. p. 1493.

Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at

onset, and development of microvascular complications in childhood-

onset type 1 diabetes: A population-based study in northern Sweden.

Diabetes Care 2004;27:955-62.

Saely CH, Aczel S, Marte T. Cardiovascular complications in type 2

diabetes mellitus depend on the coronary angiographic state rather

than on the diabetes state. Diabetologia 2004;47:145-6.

David BT, Remington: The science and practice of pharmacy. 21st ed.

Philadelphia: Lippincott Williams and Wilkins; 2005. p. 1889.

Mohan V. Handbook of diabetes mellitus. 2nd ed. Chennai: MV Diabetes

Specialities Centre and Madras Diabetes Research Foundation;

p. 99.

McEvoy GK. AHFS drug information. Bethesda: American Society of

Health-system Pharmacists, Inc; 2004. p. 3038.

Swami AM, Shetty SR, Kumar SM, Rao NV. A study on drug-drug

interaction of roxithromycin and antidiabetic drugs. Indian Drugs


Dhanabal SP. Antihyperglycemic activity of Polygala arvensis in alloxan

diabetic rats. Indian Drugs 2004;41:690-5.

Setty SR. Influence of itraconazole on sulfonylureas-induced

hypoglycemia in diabetic rats. Indian J Pharm Sci 2005;67:677-80.

Trinder P. Determination of glucose in blood using glucose oxidase

with an alternative glucose acceptor. Ann Clin Biochem 1969;6:24-7.

Satyanarayana S. Influence of quinidine, selegiline and amphotericin-B

on the pharmacokinetics and pharmacodynamics of Tolbutamide in

rabbits. Indian Drugs 1998;35:640-4.

Bressler R, Johnson DG. Pharmacological regulation of blood glucose

levels in non-insulin dependent diabetes mellitus. Arch Intern Med


Chiasson JL. Acarbose for prevention of type 2 diabetes mellitus. Am

J Med 1991;90:450.

Silva EM. Ultrasonographic abnormalities of the pancreas in IDDM and

NIDDM patients. Diabetes Care 1993;16:1296-7.

Satyanarayana S, Eswar kumar K, Rajasekar J, Thomas L, Rajanna S,

Rajanna B. Influence of aqueous extract of Fenugreek- seed powder

on the Pharmacodynamics and Pharmacokinetics of Gliclazide in rats

and rabbits. Therapy 2007;4:457-463.



  • There are currently no refbacks.